Canaccord Genuity Maintains Buy on Wave Life Sciences, Raises Price Target to $44
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
Canaccord Genuity analyst Whitney Ijem maintains Wave Life Sciences (NASDAQ:WVE) with a Buy and raises the price target from $42 to $44.
Canaccord Genuity analyst Whitney Ijem maintains Wave Life Sciences (NASDAQ:WVE) with a Buy and raises the price target from $42 to $44.